Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Calvier, L; Legchenko, E; Grimm, L; Sallmon, H; Hatch, A; Plouffe, BD; Schroeder, C; Bauersachs, J; Murthy, SK; Hansmann, G.
Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension.
Heart. 2016; 102(5):390-6 Doi: 10.1136/heartjnl-2015-308365
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Sallmon Hannes
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: BACKGROUND: Several studies have identified circulating biomarkers to be associated with the presence and severity of pulmonary arterial hypertension (PAH). Recent evidence supports a role for galectin-3 (Gal-3) and the mineralcorticoid aldosterone in left ventricular failure. However, studies on aldosterone together with Gal-3 in PAH are lacking. OBJECTIVE: We investigated a novel Aldosterone-galectin-3 (Gal-3) tandem and several other potential PAH biomarkers and their association with the disease severity. METHODS: A total of 57 patients, 41 with idiopathic PAH. (IPAH) and 16 with PAH associated with connective tissue disease (CTD), and 8 age-matched, non-relative controls were studied. Gal-3, aldosterone and other potential protein plasma concentrations were measured by single ELISA and multi-array MSD (Meso Scale Discovery) technology. RESULTS: Gal-3 values were increased in both patients with IPAH (12.2±0.6 ng/mL; p<0.05) and with PAH-CTD (14.1±1.6 ng/mL; p<0.05) versus control (8.5±0.9 ng/mL), while aldosterone was significantly elevated in IPAH only (248.5±38.8 pg/mL vs control 71.9±18.2 pg/mL; p<0.05). In addition, aldosterone, Gal-3, and N-terminal pro-brain natriuretic peptide (NT-proBNP) values were all higher in patients in WHO functional class II-III versus PAH functional class I or controls. The vascular injury marker intercellular adhesion molecule 1 (ICAM-1) was increased in IPAH and PAH-CTD versus controls (559.5±18.2 pg/mL and 734.1±59.4 pg/mL vs controls 394.8±39.3 pg/mL, p<0.05, p<0.0001, respectively), whereas vascular cell adhesion molecule 1 (VCAM-1) and proinflammatory, anti-angiogenic interleukin-12 (IL-12) were elevated in PAH-CTD only (879.5±110.0 pg/mL and 391.2±70.3 pg/mL vs controls 489.8±44.6 pg/mL, p<0.01, and 102.1±15.2 pg/mL, p<0.01, respectively). CONCLUSIONS: Heightened Gal-3 and aldosterone plasma concentrations in PAH patients indicate a role for Gal-3 signalling in the pathobiology of IPAH and PAH-CTD, and may serve as biomarkers for functional status and progression of disease.
Find related publications in this database (using NLM MeSH Indexing): Adult - administration & dosage; Aged - administration & dosage; Aldosterone - blood; Biomarkers - blood; Blood Proteins - administration & dosage; Case-Control Studies - administration & dosage; Enzyme-Linked Immunosorbent Assay - administration & dosage; Female - administration & dosage; Galectin 3 - blood; Galectins - administration & dosage; Humans - administration & dosage; Hypertension, Pulmonary - blood, diagnosis, physiopathology; Inflammation Mediators - blood; Male - administration & dosage; Middle Aged - administration & dosage; Natriuretic Peptide, Brain - blood; Peptide Fragments - blood; Predictive Value of Tests - administration & dosage; Prognosis - administration & dosage; Severity of Illness Index - administration & dosage; Up-Regulation - administration & dosage